Clinical Trials Logo

Shock, Cardiogenic clinical trials

View clinical trials related to Shock, Cardiogenic.

Filter by:

NCT ID: NCT00324766 Completed - Heart Failure Clinical Trials

Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.

Start date: June 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of a 24 hour infusion with levosimendan in patients with acute myocardial infarction and heart failure after acute percutaneous coronary intervention (PCI) treatment.

NCT ID: NCT00157144 Completed - Clinical trials for Respiratory Insufficiency

Australia and New Zealand Adult Extracorporeal Membrane Oxygenation (ECMO) Audit 2005

Start date: October 2004
Phase: N/A
Study type: Observational

Extracorporeal membrane oxygenation (ECMO) is a means of artificially performing the function of the human lung and/or heart outside the body. Its use is escalating in a wide range of clinical settings in the adult population without evidence or guidelines to support this practice. This study involves a nationwide questionnaire which has two components. The initial pilot survey will attempt to identify all institutions currently practicing ECMO or those intending to do so in the future, and are willing to participate in prospective data collection. The second phase will involve a monthly survey of these centres regarding the extent of ECMO use, practice details implemented, and outcome data. It is hoped that the collection of this information will later assist in the development of guidelines for this expensive and presently unsubstantiated practice, together with the construction of appropriate training programs for staff.

NCT ID: NCT00000552 Completed - Clinical trials for Cardiovascular Diseases

Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.

Start date: September 1994
Phase: Phase 3
Study type: Interventional

To test if early revascularization, primarily with angioplasty (PTCA) or bypass surgery (CABG), reduced all-cause in-hospital mortality from cardiogenic shock compared to conventional treatment, including thrombolysis.